Evidence map›Paper›PMID 36118167›Full record

ArticleOpen life sciences2022

Pei Shen, Xianjuan Shen, Guo Chen, Chunmei Zhao, Hua Cai, Xinxin Xu, Yinong Duan, Xudong Wang, Shaoqing Ju

Open access · goldAbstract read
In one paragraph

Article in Open life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Pei ShenLaboratory Medicine Center, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu, People's Republic of China.
Xianjuan ShenLaboratory Medicine Center, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu, People's Republic of China.
Guo ChenDepartment of Pathogen Biology, School of Medicine, Nantong University, 19 Qixiu Road, Nantong 226001, Jiangsu, People's Republic of China.
Chunmei ZhaoLaboratory Medicine Center, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu, People's Republic of China.
Hua CaiLaboratory Medicine Center, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu, People's Republic of China.
Xinxin XuLaboratory Medicine Center, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu, People's Republic of China.
Yinong DuanDepartment of Pathogen Biology, School of Medicine, Nantong University, 19 Qixiu Road, Nantong 226001, Jiangsu, People's Republic of China.
Xudong WangLaboratory Medicine Center, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu, People's Republic of China.
Shaoqing JuLaboratory Medicine Center, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong 226001, Jiangsu, People's Republic of China.
Nantong University · CNAffiliated Hospital of Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TIPE1 is a gene in the TNFAIP8 family involved in immune regulation and tumorigenesis. Although previous studies demonstrated that TIPE1 might play different roles in different tumors, its expression and role in lymphoma are unclear. Here we observed TIPE1 expression in diffuse large B cell lymphoma (DLBCL). Two microarrays containing 96 tumor tissue specimens were obtained from the Affiliated Hospital of Nantong University biobank. All specimens came from patients with a clear pathological diagnosis of lymphoma, lymphadenitis, breast cancer, or bladder cancer, and we performed immunohistochemical experiments on these tissue specimens. GEPIA and TIMER platforms were used for bioinformatic analyses. We found higher TIPE1 expression in tumor tissues from patients with lymphoma compared with those with lymphadenitis, breast cancer, or bladder cancer. The GEPIA and TIMER analyses revealed that TIPE1 was upregulated in DLBCL tissues but not in invasive breast carcinoma, urothelial bladder carcinoma, or liver hepatocellular carcinoma tissues. TIPE1 expression was irrelevant for pathological stage, overall survival, or DLBCL immune infiltration levels. However, TIPE1 expression was correlated with MKI67 expression in DLBCL. Overall, TIPE1's high expression levels in DLBCL may contribute to tumor growth in DLBCL.

Indexed as

diffuse large B cell lymphomalymphomaTIPE1

Identifiers

PMID36118167
PMCPMC9438966
OpenAlexW4294232995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.